Achieve's anti-smoking drug beats placebo in 2nd phase 3, keeping biotech on course for FDA filing

Achieve Life Sciences’ smoking cessation drug candidate cytisinicline has hit the mark in a second phase 3 clinical trial, filling in a key gap in the evidence needed to support approval. But, amid lingering doubts about the asset’s commercial prospects, Achieve still has a sub-$200 million market cap.